摘要
目的探讨多西他赛+铂类药物治疗食管癌患者的疗效。方法选取2016年2月至2019年1月于上饶市第五人民医院接受治疗的食管癌患者62例作为研究对象,随机分为对照组与观察组,每组31例。对照组采用替吉奥联合卡铂治疗,观察组采用多西他赛联合铂类药物治疗,比较两组治疗效果、生存率、生存期及不良反应发生情况。结果观察组治疗有效率为93.55%(29/31),明显高于对照组的70.97%(22/31),差异有统计学意义(χ^2=5.415,P=0.020);对照组生存率为45.16%(14/31)、生存期为(25.58±7.67)个月,观察组生存率为70.97%(22/31)、生存期为(29.52±6.67)个月,观察组生存率、生存期优于对照组,差异有统计学意义(χ^2=4.239,P=0.040;t=2.158,P=0.035);观察组不良反应发生率为9.68%(3/31),明显低于对照组的38.71%(12/31),差异有统计学意义(χ^2=7.123,P=0.008)。结论多西他赛联合铂类药物治疗食道癌效果确切,可提高患者生存率,延长生存期,且不良反应少,安全性较高。
Objective To explore the efficacy of Docetaxel plus platinum drugs in the treatment of patients with esophageal cancer. Method From February 2016 to January 2019, 62 patients with esophageal cancer who were treated in the Fifth People’s Hospital of Shangrao City were randomly divided into control group and observation group with 31 cases in each group. The control group was treated with tegeor combined with carboplatin, and the observation group was treated with Docetaxel combined with platinum drugs. Results The effective rate of the observation group was 93.55%(29/31), which was significantly higher than that of the control group(70.97%)(22/31)(χ^2=5.415, P=0.020);The survival rate of the control group was 45.16%(14/31), and the survival time was(25.58±7.67) months. The survival rate of the observation group was 70.97%(22/31) and the survival time was(29.52±6.67). Compared with the control group, the survival rate and the survival time of the observation group were superior. The difference was statistically significant(χ^2=4.239, P=0.040;t=2.158, P=0.035). The incidence of adverse reactions in the observation group was 9.68%(3/31), significantly lower than 38.71%(12/31) in the control group, the difference was statistically significant(χ^2=7.123, P=0.008). Conclusion Docetaxel combined with platinum drugs is effective in the treatment of esophageal cancer, which can improve the survival rate and prolong the survival period of patients, with less adverse reactions and high safety.
作者
徐晓暇
XU Xiao-Xia(Department One of Oncology,The Fifth People's Hospital of Shangrao City,Shangrao 334000,China)
出处
《中国药物经济学》
2019年第12期89-91,共3页
China Journal of Pharmaceutical Economics
关键词
食管癌
多西他赛
铂类药物
生存期
Esophageal cancer
Docetaxel
Platinum drugs
Survival
